Large differencies in age-specific survival in multiple myeloma in the nordic countries

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F24%3A10478589" target="_blank" >RIV/00216208:11140/24:10478589 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MKngu.X92g" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MKngu.X92g</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41408-024-01026-6" target="_blank" >10.1038/s41408-024-01026-6</a>

Result language
angličtina
Original language name
Large differencies in age-specific survival in multiple myeloma in the nordic countries
Original language description
Treatment of multiple myeloma (MM), like most hematological neoplasms, has developed fast and completely novel therapeutic modalities have been introduced. In the late 1980s autologous stem cell transplantation (ASCT) was introduced in hematology, and for MM it was used in combination with high-dose melphalan treatment. Eligibility for ASCT was considered by fitness of the patients and their age (<65 years), which however has been increased to 70 or 75 years. In the Nordic countries some 30% of MM patients undergo this primary treatment.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
<a href="/en/project/EH22_008%2F0004644" target="_blank" >EH22_008/0004644: Saving lives through research in early cancer detection and prevention: Molecular, genomic and societal factors</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)